Article info

Download PDFPDF

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
Free

Authors

  • D L Scott aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • J S Smolen aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • J R Kalden aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • L B A van de Putte aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • A Larsen aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • T K Kvien aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • M Schattenkirchner aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • P Nash aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • C Oed aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  • I Loew-Friedrich aKing's College Hospital, London, UK, bUniversity of Vienna, Vienna, Austria, cUniversity Erlangen-Nuremberg, Erlangen, Germany, dUniversity Hospital Nijmegen, Nijmegen, The Netherlands, eKongsvinger Sjukehus, Kongsvinger, Norway, fDiakonhjemmet Hospital, Oslo, Norway, gUniversity of Munich, Munich, Germany, hSixth Avenue Specialist Centre, Queensland, Australia, iAventis Pharma PubMed articlesGoogle scholar articles
  1. Professor D L Scott, King's College Hospital, East Dulwich Grove, Dulwich, London SE22 8PT, UKleigh.joyce{at}kcl.ac.uk
View Full Text

Citation

Scott DL, Smolen JS, Kalden JR for the European Leflunomide Study Group, et al
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

Publication history

  • Accepted March 6, 2001
  • First published October 1, 2001.
Online issue publication 
October 01, 2001

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.